Valneva SE VALN
NASDAQ VALN
$6.89 -0.17 (-2.41%)
At close: Sep 4, 2026 · 4:00 PM EDT

Valneva SE (VALN) Liabilities and Shareholders Equity (2020 - 2026)

Valneva SE (VALN) posted Liabilities and Shareholders Equity of $435.5 million for Q1 2026, down 6.19% sequentially from $464.3 million in Q4 2025, and down 14.14% YoY from $507.3 million in Q1 2025.

Analysis

Valneva SE (VALN) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends

Valneva SE has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $435.5 million in Q1 2026.

  • Quarterly Liabilities and Shareholders Equity fell 14.14% year-over-year to $435.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 billion (down 7.23% YoY) and the FY2025 annual result came in at $464.3 million, down 14.22% from the prior year.
  • Liabilities and Shareholders Equity eased to $435.5 million in Q1 2026 per VALN's latest filing, from $464.3 million in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $872.9 million in Q1 2022 and troughed at $435.5 million in Q1 2026.
  • A 5-year average of $581.6 million and a median of $546.3 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
  • The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity sank 32.2% in 2022, then advanced 7.95% in 2024.
  • Over 5 years, Liabilities and Shareholders Equity stood at $633.9 million in 2022, then decreased by 21.92% to $495.0 million in 2023, then rose by 7.95% to $534.3 million in 2024, then fell by 13.11% to $464.3 million in 2025, then dropped by 6.19% to $435.5 million in 2026.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $435.5 million, $464.3 million, and $524.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 27.42 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 41.73 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 10.03 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 10.96 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 4.32 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 9.18 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 5.56 Bn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 19.82 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 2.10 Bn
10 Valneva SE 578.54 Mn 437.28 Mn 1.86 Mn 451.32 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 451.32 Mn
Mar 31, 2026 435.53 Mn
Dec 31, 2025 464.26 Mn
Sep 30, 2025 524.00 Mn
Jun 30, 2025 534.99 Mn
Mar 31, 2025 507.26 Mn
Dec 31, 2024 534.33 Mn
Sep 30, 2024 567.36 Mn
Jun 30, 2024 502.44 Mn
Mar 31, 2024 546.25 Mn
Dec 31, 2023 495.00 Mn
Sep 30, 2023 566.65 Mn
Jun 30, 2023 590.82 Mn
Mar 31, 2023 633.27 Mn
Dec 31, 2022 633.92 Mn
Sep 30, 2022 703.86 Mn
Jun 30, 2022 773.73 Mn
Mar 31, 2022 872.85 Mn
Dec 31, 2021 935.03 Mn
Dec 31, 2020 535.53 Mn